Adam Halberstadt
Associate Professor of Psychiatry and Psychopharmacology Director at the UC San Diego Center for Psychedelic Research
Data updated
Research Footprint
Adam Halberstadt appears in 12 tracked papers (2010–2024), most studied alongside Psilocybin, LSD and Mescaline, across Medicinal Chemistry & Drug Development, Depressive Disorders and Anxiety Disorders.
Most-cited paper: Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer (1209 citations).
Frequent co-authors: John McCorvy, Simon Brandt and Yasmin Schmid.
Background & Research
Adam L. Halberstadt, Ph.D., is an Associate Professor of Psychiatry at the University of California San Diego and Psychopharmacology Director at the UC San Diego Center for Psychedelic Research. He received his B.A. in Neuroscience from the University of Delaware and his Ph.D. in Neurobiology from the University of Pittsburgh, then completed postdoctoral training at UC San Diego focused on the behavioral effects of serotonergic hallucinogens. His work has helped define animal models and receptor pathways used to study psychedelic compounds and their therapeutic potential.
Key Impact
He is a leading behavioral pharmacologist studying serotonergic hallucinogens, including head-twitch response models, receptor mechanisms, and psychedelic analogs relevant to psychiatry.
Collaboration Network
13 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Adam Halberstadt is associated with.